雅虎香港財經 Here’s Why Gilead Sciences (GILD) Outperformed in Q4
Ariel Investments, an investment management company, released its “Ariel Global Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here. In the fourth quarter, the Ariel Global Composite delivered a 10.72% gross of fees compared to a +9.76% return for the primary MSCI ACWI Index and a +14.21% gain for the MSCI ACWI Value Index. In addition, you can check the top 5 holdings of the fund to know its best picks in 2022.
Ariel Global Strategy highlighted stocks like Gilead Sciences, Inc. (NASDAQ:GILD) in the Q4 2022 investor letter. Headquartered in Foster City, California, Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company. On March 15, 2023, Gilead Sciences, Inc. (NASDAQ:GILD) stock closed at $79.65 per share. One-month return of Gilead Sciences, Inc. (NASDAQ:GILD) was -4.48%, and its shares gained 34.54% of their value over the last 52 weeks. Gilead Sciences, Inc. (NASDAQ:GILD) has a market capitalization of $99.444 billion.
Ariel Global Strategy made the following comment about Gilead Sciences, Inc. (NASDAQ:GILD) in its Q4 2022 investor letter:
"Biopharmaceutical company Gilead Sciences, Inc. (NASDAQ:GILD. advanced in the quarter on positive data released in a study evaluating Trodelvy versus comparative chemotherapy in patients with metastatic breast cancer. The detailed findings increased investor confidence the drug would receive incremental approvals for a broader range of breast cancer treatments. Shares also received a boost on news the TAF patent portfolio for HIV drugs will be extended from the middle of this decade through the early 2030s, creating greater visibility into the company’s long-term opportunity in the virology market."
Copyright: dolgachov / 123RF Stock Photo
Gilead Sciences, Inc. (NASDAQ:GILD) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 64 hedge fund portfolios held Gilead Sciences, Inc. (NASDAQ:GILD) at the end of the fourth quarter which was 56 in the previous quarter.
We discussed Gilead Sciences, Inc. (NASDAQ:GILD) in another article and shared ClearBridge Sustainability Leaders Strategy’s views on the company. In addition, please check out our hedge fund investor letters Q4 2022 page for more investor letters from hedge funds and other leading investors.
Suggested Articles:
Disclosure: None. This article is originally published at Insider Monkey.
